MGROF Stock Chart & Stats
$0.34
-$0.03(-11.58%)
At close: 4:00 PM EDT
$0.34
-$0.03(-11.58%)
Day’s Range― - ―
52-Week Range$0.22 - $0.68
Previous CloseN/A
Volume4.50K
Average Volume (3M)5.24K
Market Cap
$21.13M
Enterprise Value$20.73
Total Cash (Recent Filing)$4.37M
Total Debt (Recent Filing)$515.57K
Price to Earnings (P/E)―
Beta0.31
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding70,441,360
10 Day Avg. Volume2,990
30 Day Avg. Volume5,238
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)39.49
Price to Sales (P/S)4.13
P/FCF Ratio-5.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$18.39M
Bulls Say, Bears Say
Bulls Say
Low LeverageModest leverage reduces near-term balance-sheet risk and leaves the company less exposed to mandatory debt servicing than a highly indebted business. This provides some financial flexibility while management works to improve commercialization, revenue scale, and operating results.
Improved Gross MarginA gross margin near 53% indicates the company retains meaningful economics on the revenue it generates, even before reaching profitability. If maintained as sales scale, this margin provides a foundation for operating leverage and could help narrow losses over time.
Partner-led Biologic Commercialization ModelA commercialization model centered on established agriculture input partners can allow MustGrow to monetize intellectual property without building a large direct-to-farm distribution operation. Successful approvals and partner execution could support scalable royalty and milestone income.
Bears Say
Sharp Revenue ContractionRecent top-line contraction shows that commercial revenue remains inconsistent and has not yet established a durable growth trajectory. Continued weakness would reduce the resources available for research, regulatory progress, commercialization support, and the eventual absorption of fixed costs.
Deep And Persistent LossesLarge operating and net losses indicate that current revenue is far below the scale needed to support the cost structure. Unless commercialization expands materially or expenses decline, persistent losses can erode equity value and constrain the company’s ability to fund growth internally.
Ongoing Cash ConsumptionNegative operating and free cash flow means the business is consuming cash rather than funding its activities from operations. If this pattern persists, MustGrow may become increasingly reliant on external financing, creating pressure on strategic flexibility and shareholder value.
MustGrow Biologics News
MGROF FAQ
What was MustGrow Biologics’s price range in the past 12 months?
MustGrow Biologics lowest stock price was $0.22 and its highest was $0.68 in the past 12 months.
What is MustGrow Biologics’s market cap?
MustGrow Biologics’s market cap is $21.13M.
When is MustGrow Biologics’s upcoming earnings report date?
MustGrow Biologics’s upcoming earnings report date is Dec 01, 2026 which is in 85 days.
How were MustGrow Biologics’s earnings last quarter?
MustGrow Biologics released its earnings results on Aug 27, 2026. The company reported $0 earnings per share for the quarter.
Is MustGrow Biologics overvalued?
According to Wall Street analysts MustGrow Biologics’s price is currently Overvalued.
Does MustGrow Biologics pay dividends?
MustGrow Biologics does not currently pay dividends.
What is MustGrow Biologics’s EPS estimate?
MustGrow Biologics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MustGrow Biologics have?
MustGrow Biologics has 70,441,360 shares outstanding.
What happened to MustGrow Biologics’s price movement after its last earnings report?
MustGrow Biologics reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went up 5.296%.
Which hedge fund is a major shareholder of MustGrow Biologics?
Currently, no hedge funds are holding shares in MGROF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MustGrow Biologics
MustGrow Biologics Corp. is an agricultural biotechnology enterprise specializing in the creation and commercialization of natural crop protection solutions. These offerings, including biopesticides, biofumigants, and bioherbicides, are uniquely derived from mustard seed. The company provides a pre-planting soil biofumigation technique aimed at combating soil-borne diseases and pests across diverse agricultural commodities, such as fruits and vegetables. Furthermore, MustGrow is actively developing a bioherbicide to manage undesirable plant growth, intended for use in organic farming, home gardens, and broader agricultural sectors. Their portfolio also extends to post-harvest food preservation, applying treatments to inhibit sprouting, disease, and pathogens, thereby enhancing the shelf life of stored products. A significant offering is CannaPM, an active compound effective against both fungal soil ailments and foliar diseases. Established in 2014 and headquartered in Saskatoon, Canada, the company adopted the name MustGrow Biologics Corp. in March 2018, having previously operated as Duport Capital Ltd.
MGROF Earnings Call
Q2 2026
0:00 / 0:00
Technical Analysis
Progressive Planet Solutions Inc
―
Bee Vectoring Technologies International
―
Gensource Potash
―
Verde Agritech
―
Nutrien
―
Ownership Overview
10.91% Insiders
―
Mutual Funds
― Other Institutional Investors
89.09% Public Companies and
Individual Investors